 OncoSec Medical Incorporated NASDAQ:ONCS the Company or OncoSec, a company developing late-stage intratumoral cancer immunotherapies, today announced Notices of Allowance for three new patent applications covering its interleukin-12 IL-12 based immunotherapy platform, including its lead product candidate TAVOTM and next-generation product candidate TAVOPLUS, and electroporation gene delivery system. 